GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Antibody
Comment: Fianlimab (R3767; REGN3767) is a monoclonal antibody that targets the inhibitory immune checkpoint co-receptor lymphocyte activation gene-3 protein (LAG3; CD223) on tumour infiltrating lymphocytes [1]. It was proposed for immunotherapeutic antineoplastic activity.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Fianlimab (REGN3767) was progressed to clinical studies to evaluate safety and efficacy as a treament for advanced solid tumours. In most studies REGN3767 was administered in combination with other immune checkpoint inhibtors or anti-tumour chemotherapeutics. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06246916 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 Interventional | Regeneron Pharmaceuticals | ||
| NCT06571708 | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) | Phase 2 Interventional | Columbia University | ||
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 Interventional | Regeneron Pharmaceuticals | ||
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | Phase 2 Interventional | Regeneron Pharmaceuticals | ||
| NCT06848088 | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | Phase 2 Interventional | Regeneron Pharmaceuticals | ||
| NCT06918132 | Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer | Phase 2 Interventional | Mayo Clinic | ||
| NCT05608291 | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | Phase 3 Interventional | Regeneron Pharmaceuticals | In a press release (May 2026) Regeneron reported that REGN3767 + anti-PD-1 |
|
